Cargando…

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Detalles Bibliográficos
Autores principales:	Cohen, Hillel P., Blauvelt, Andrew, Rifkin, Robert M., Danese, Silvio, Gokhale, Sameer B., Woollett, Gillian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993848/ https://www.ncbi.nlm.nih.gov/pubmed/29785563 http://dx.doi.org/10.1007/s40265-018-0919-1

Ejemplares similares

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch
por: Sagi, Sreedhar, et al.
Publicado: (2023)

An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Authors’ reply
por: Gokhale, Nikhil S
Publicado: (2016)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

Discussion suite à la communication : « PCR et paléogénétique : pour le meilleur et pour le pire »()
por: Geigl, E.-M.
Publicado: (2021)

El padre Pire y la Europa del corazón
por: Weyergans, Franz
Publicado: (1959)

Patient involvement in research priorities (PIRE): a study protocol
por: Piil, Karin, et al.
Publicado: (2016)

Terroristes présumés arrêtés On a peut-être évité le pire
Publicado: (2009)

Authors’ reply to Grundtvig Gram et al.
por: Hofmann, Bjørn, et al.
Publicado: (2021)

The Importance of Countering Biosimilar Disparagement and Misinformation
por: Cohen, Hillel P., et al.
Publicado: (2020)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Authors' reply to letters from Egilman et al and Oliver et al
por: Peto, Julian, et al.
Publicado: (2016)

Authors’ Reply to: VanderWeele et al., Chiolero, and Schooling et al.
por: Broadbent, Alex, et al.
Publicado: (2016)

Authors’ reply to the comment from Uchida et al.
por: Osawa, Itsuki, et al.
Publicado: (2023)

Authors’ reply to the comment from Glass et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Authors’ Reply
por: Pramanik, Raja, et al.
Publicado: (2021)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Commentary: A Comment on Qi et al.—Authors’ Reply
por: Qi, X. Sharon, et al.
Publicado: (2012)

Authors’ reply to the comment from Benavides-Zora et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
por: Woollett, Gillian R., et al.
Publicado: (2022)

The authors reply: Letter on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Clark et al.
por: Buckinx, Fanny, et al.
Publicado: (2019)

Pire que l’épidémie : l’infodémie, le côté sombre des réseaux sociaux
por: Manus, Jean-Marie
Publicado: (2020)

Author's Reply
por: Hoyt, Brian S, et al.
Publicado: (2014)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?
por: McCamish, M, et al.
Publicado: (2013)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2tesfvo61r6kvbhvgncbtq2ume